Junction vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 38)
Junction logo

Junction

EmergingHealthcare

General

US YC health data API infrastructure connecting 500+ wearables and at-home lab tests for 140+ healthcare orgs; $18M Creandum Series A Mar 2025 supporting 2M+ connected devices and 500K+ tests annually competing with Validic and Terra API.

AI VisibilityBeta
Overall Score
D38
Category Rank
#461 of 596
AI Consensus
81%
Trend
up
Per Platform
ChatGPT
42
Perplexity
37
Gemini
42

About

Junction is a United States-based health data infrastructure company — backed by Y Combinator with $18 million in Series A funding in March 2025 led by Creandum with participation from Point Nine, Amino Collective, and Inflect Health — providing digital health companies, research organizations, and healthcare technology platforms with a unified API infrastructure for collecting wearable device data (500+ supported devices including Apple Watch, Fitbit, Oura, Garmin, and continuous glucose monitors) and delivering at-home diagnostic test kits to patients with automated diagnostic data workflows that connect labs, wearables, and health systems. Founded and serving 140+ healthcare organizations including Found, Parsley Health, and Evidation, Junction supports 500,000+ lab tests annually and 2 million+ connected devices.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

38
Overall Score
88
#461
Category Rank
#3
81
AI Consensus
78
up
Trend
stable
42
ChatGPT
83
37
Perplexity
87
42
Gemini
85
35
Claude
90
39
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.